ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

11,249Medicare Part D Prescriptions Filled, Including Refills

Rank: 167 out of 1844

$645K Total Retail Price of All Prescriptions

Rank: 180 out of 1844

433 Patients Receiving at Least One Drug in Part D
83%Patients 65 Years and Older
92% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Indiana
Lower avg

Schedule Two
Controlled Substances

7% of this provider’s 433 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

13% of this provider’s 433 patients filled at least one prescription for a schedule three drug, compared to an average of 15%.

Risky Drugs to Seniors

0% of this provider’s 9,650 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

25% of this provider’s prescriptions were for brand-name drugs, compared to an average of 24%.

Prescription Price

$57 was the average price of a prescription from this provider, compared to $60 among peers.

Prescriptions per Patient

26 is the average number of prescriptions (including refills) per patient, compared to an average of 20.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Indiana
LEVOTHYROXINE SODIUM 522 463 1 1
FUROSEMIDE 429 393 2 7
SIMVASTATIN 389 321 3 3
WARFARIN SODIUM 377 356 4 13
DONEPEZIL HCL 354 333 5 26
OMEPRAZOLE 331 295 6 5
LISINOPRIL 329 280 7 4
CITALOPRAM HBR 289 268 8 19
CYMBALTA 279 245 9 36
NAMENDA 257 244 10 33
HYDROCODONE-ACETAMINOPHEN 248 201 S3 11 2
POLYETHYLENE GLYCOL 3350 247 242 12 39
METOPROLOL TARTRATE 239 205 13 11
AMLODIPINE BESYLATE 205 201 14 6
DIVALPROEX SODIUM 190 169 15 74
MIRTAZAPINE 173 154 16 49
RISPERIDONE 170 160 17 65
POTASSIUM CHLORIDE 166 162 18 16
KLOR-CON M20 155 144 19 54
TRAZODONE HCL 143 120 20 43
SPIRIVA 128 128 21 57
IPRATROPIUM-ALBUTEROL 118 106 22 113
LOSARTAN POTASSIUM 111 111 23 24
SERTRALINE HCL 107 77 24 21
CARVEDILOL 107 98 24 22
LEVETIRACETAM 106 75 26 105
NOVOLOG MIX 70-30 104 102 27 266
OLANZAPINE 104 100 27 117
GABAPENTIN 103 76 29 15
ISOSORBIDE MONONITRATE ER 96 96 30 59
FLUTICASONE PROPIONATE 92 89 31 50
METOPROLOL SUCCINATE 92 92 31 14
LANTUS 90 70 33 42
HUMALOG 88 81 34 114
PREDNISONE 77 66 35 40
ADVAIR DISKUS 73 73 36 51
FAMOTIDINE 71 71 37 63
GLIPIZIDE 71 36 37 70
TRAMADOL HCL 65 65 39 18
HYDROCHLOROTHIAZIDE 64 51 40 9
CEPHALEXIN 63 38 41 56
BACLOFEN 63 26 41 119
ABILIFY 63 38 41 150
QUETIAPINE FUMARATE 58 56 44 82
ROPINIROLE HCL 56 39 45 76
CARBIDOPA-LEVODOPA 56 56 45 86
RANITIDINE HCL 55 40 47 38
NOVOLOG 55 27 47 84
ALENDRONATE SODIUM 55 55 47 25
HYDRALAZINE HCL 55 55 47 120
LIDODERM 52 52 51 155
NYSTATIN 51 39 52 85
TAMSULOSIN HCL 51 36 52 27
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 9, 2014.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.